{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:10:38Z","timestamp":1767474638350,"version":"3.48.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Traditional Chinese Scientific and Technological Projects for Medicine and Health of Zhejiang Province","award":["2025ZL004"],"award-info":[{"award-number":["2025ZL004"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Current guidelines recommend medical treatment for heart failure with preserved ejection fraction (HFpEF) but do not address inotropic drug use during acute HF episodes. This real-world study aimed to evaluate the effects of levosimendan in elderly patients presenting with acute HFpEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified patients aged\u2009\u2265\u200965 years hospitalized with acute HFpEF at our institution. Using propensity score matching (PSM), 160 patients were selected. Echocardiographic parameters and B-type natriuretic peptide (BNP) levels were assessed before and after levosimendan administration. Rehospitalization for heart failure (HF) and all-cause mortality were compared during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Multivariable analysis revealed significantly greater improvements in the levosimendan group for septal early diastolic mitral inflow velocity to mitral annular tissue velocity ratio (E\/e\u2019) (\u0394E\/e\u2019: -2.4\u2009\u00b1\u20092.4 vs. -1.9\u2009\u00b1\u20092.1; t = -2.09, 95% CI: -0.76 to -0.02; p\u2009=\u20090.038) and New York Heart Association (NYHA) class [median change: -1 (-1 to -0.25) vs. -1(-1 to 0); p\u2009=\u20090.048]. No significant between-group differences were observed in \u0394BNP, \u0394absolute global longitudinal strain (\u0394aGLS), \u0394left ventricular ejection fraction (\u0394LVEF), or hospital length of stay. Subgroup analyses demonstrated greater improvements in \u0394aGLS and \u0394septal E\/e\u2019 among patients with baseline aGLS\u2009&lt;\u200916% or septal E\/e\u2019 \u226515. After a median follow-up of 12.5 months, composite outcomes of rehospitalization for HF and all-cause mortality did not differ significantly between groups (levosimendan 21 vs. control 23; Log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.095).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>For older patients with acute HFpEF combined with more comorbidities, although levosimendan may transiently improve hemodynamics and functional capacity in the acute phase, it fails to demonstrate long-term prognostic benefits. The clinical benefit of this drug may be limited to select patients, and its clinical application may lack cost-effectiveness for broader application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12872-025-05224-3","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T11:43:13Z","timestamp":1764157393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of levosimendan for acute decompensated heart failure with preserved ejection fraction in the elderly: a single-center retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaohong","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangchao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenkai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxiu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"issue":"18","key":"5224_CR1","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1161\/cir.0000000000001062","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/ HFSA guideline for the management of heart failure: executive summary: a report of the American college of Cardiology\/ American heart association joint committee on clinical practice guidelines. Circulation. 2022;145(18):e876-94. https:\/\/doi.org\/10.1161\/cir.0000000000001062.","journal-title":"Circulation"},{"issue":"10","key":"5224_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329(10):827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"issue":"8","key":"5224_CR3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-621. https:\/\/doi.org\/10.1161\/CIR.0000000000001123.","journal-title":"Circulation"},{"issue":"1","key":"5224_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-AviV, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1\u2013e3914. https:\/\/doi.org\/10.1016\/j.echo.2014.10.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"40","key":"5224_CR5","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","volume":"40","author":"B Pieske","year":"2019","unstructured":"Pieske B, Tsch\u00f6pe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the heart failure association (HFA) of the European society of cardiology (ESC). Eur Heart J. 2019;40(40):3297\u2013317. https:\/\/doi.org\/10.1093\/eurheartj\/ehz641.","journal-title":"Eur Heart J"},{"issue":"6","key":"5224_CR6","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.echo.2011.02.004","volume":"24","author":"DA Morris","year":"2011","unstructured":"Morris DA, Gailani M, Vaz P\u00e9rez A, et al. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. J Am Soc Echocardiogr. 2011;24(6):651\u201362.","journal-title":"J Am Soc Echocardiogr"},{"issue":"2","key":"5224_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ehjci\/jeu299","volume":"16","author":"M Garbi","year":"2015","unstructured":"Garbi M, McDonagh T, Cosyns B, et al. Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. Eur Heart J Cardiovasc Imaging. 2015;16(2):147\u201353. https:\/\/doi.org\/10.1093\/ehjci\/jeu299.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"5224_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.echo.2014.11.003","volume":"28","author":"JU Voigt","year":"2015","unstructured":"Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry task force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28(2):183\u201393. https:\/\/doi.org\/10.1016\/j.echo.2014.11.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"12","key":"5224_CR9","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.amjcard.2017.03.032","volume":"119","author":"W Huang","year":"2017","unstructured":"Huang W, Chai SC, Lee SGS, MacDonald MR, Leong KTG. Prognostic factors after index hospitalization for heart failure with preserved ejection fraction. Am J Cardiol. 2017;119(12):2017\u201320. https:\/\/doi.org\/10.1016\/j.amjcard.2017.03.032.","journal-title":"Am J Cardiol"},{"issue":"37","key":"5224_CR10","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"1","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, ESC Scientific Document Group. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;1(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"6A","key":"5224_CR11","doi-asserted-by":"publisher","first-page":"G68","DOI":"10.1016\/j.amjcard.2005.07.023","volume":"96","author":"M Gheorghiade","year":"2005","unstructured":"Gheorghiade M, Teerlink JR, Mebazaa A. Pharmacology of new agents for acute heart failure syndromes. Am J Cardiol. 2005;96(6A):G68\u201373. https:\/\/doi.org\/10.1016\/j.amjcard.2005.07.023.","journal-title":"Am J Cardiol"},{"issue":"2","key":"5224_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/CIRCULATIONAHA.105.542407","volume":"113","author":"DA Kass","year":"2006","unstructured":"Kass DA, Solaro RJ. Mechanisms and use of calcium sensitizing agents in the failing heart. Circulation. 2006;113(2):305\u201315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.542407.","journal-title":"Circulation"},{"issue":"3","key":"5224_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/FJC.0000000000000533","volume":"71","author":"J Altenberger","year":"2018","unstructured":"Altenberger J, Gustafsson F, Harjola VP, et al. Levosimendan in acute and advanced heart failure: an appraisal of the clinical database and evaluation of its therapeutic applications. J Cardiovasc Pharmacol. 2018;71(3):129\u201336. https:\/\/doi.org\/10.1097\/FJC.0000000000000533.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"5224_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jchf.2012.12.004","volume":"1","author":"M Packer","year":"2013","unstructured":"Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC: Heart Failure. 2013;1(2):103\u201311. https:\/\/doi.org\/10.1016\/j.jchf.2012.12.004.","journal-title":"JACC: Heart Failure"},{"issue":"4","key":"5224_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.18087\/cardio.2020.4.n788","volume":"60","author":"T Unurjargal","year":"2020","unstructured":"Unurjargal T, Khorloo C, Ulziisaikhan G, et al. Screening for asymptomatic heart failure with preserved ejection fraction in Mongolian population at high risk. Kardiologiia. 2020;60(4):86\u201390. https:\/\/doi.org\/10.18087\/cardio.2020.4.n788.","journal-title":"Kardiologiia"},{"issue":"6","key":"5224_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/ehjci\/jey042","volume":"19","author":"LP Badano","year":"2018","unstructured":"Badano LP, Kolias TJ, Muraru D, et al. Standardization of left atrial right ventricular and right atrial deformation imaging using two-dimensional speckle tracking echocardiography a consensus document of the EACVI\/ASE\/Industry task force to standardize deformation imaging. Eur Heart J Cardiovasc Imaging. 2018;19(6):591\u2013600. https:\/\/doi.org\/10.1093\/ehjci\/jey042.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"2","key":"5224_CR17","doi-asserted-by":"publisher","first-page":"e000630","DOI":"10.1136\/openhrt-2017-000630","volume":"4","author":"DA Morris","year":"2017","unstructured":"Morris DA, Ma XX, Belyavskiy E, et al. Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis. Open Hear. 2017;4(2):e000630. https:\/\/doi.org\/10.1136\/openhrt-2017-000630.","journal-title":"Open Hear"},{"issue":"7","key":"5224_CR18","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20209646","volume":"53","author":"C Ma","year":"2020","unstructured":"Ma C, Luo H, Fan L, et al. Heart failure with preserved ejection fraction: an update on pathophysiology, diagnosis, treatment, and prognosis. Braz J Med Biol Res. 2020;53(7):e9646. https:\/\/doi.org\/10.1590\/1414-431x20209646.","journal-title":"Braz J Med Biol Res"},{"issue":"7","key":"5224_CR19","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1056\/NEJMcibr1913825","volume":"382","author":"WJ Paulus","year":"2020","unstructured":"Paulus WJ. Unfolding discoveries in heart failure. N Engl J Med. 2020;382(7):679\u201382. https:\/\/doi.org\/10.1056\/NEJMcibr1913825.","journal-title":"N Engl J Med"},{"issue":"5","key":"5224_CR20","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.jacc.2013.09.052","volume":"63","author":"E Kraigher-Krainer","year":"2014","unstructured":"Kraigher-Krainer E, Shah AM, Gupta DK, et al. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(5):447\u201356.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5224_CR21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1093\/ehjci\/jex005","volume":"18","author":"E Donal","year":"2017","unstructured":"Donal E, Lund LH, Oger E, et al. Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fraction. Eur Hear J - Cardiovasc Imaging. 2017;18(6):629\u201335. https:\/\/doi.org\/10.1093\/ehjci\/jex005.","journal-title":"Eur Hear J - Cardiovasc Imaging"},{"issue":"4","key":"5224_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/EHF2.12159","volume":"4","author":"J Buggey","year":"2017","unstructured":"Buggey J, Alenezi F, Yoon HJ, et al. Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. ESC Heart Fail. 2017;4(4):432\u20139. https:\/\/doi.org\/10.1002\/EHF2.12159.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"5224_CR23","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.111.000045.25","volume":"6","author":"CL Clarke","year":"2013","unstructured":"Clarke CL, Grunwald GK, Allen LA, et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(6):680\u20136. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.111.000045.25.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"10","key":"5224_CR24","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/ejhf.2947","volume":"25","author":"A Brann","year":"2023","unstructured":"Brann A, Miller J, Eshraghian E, et al. Global longitudinal strain predicts clinical outcomes in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2023;25(10):1755\u201365. https:\/\/doi.org\/10.1002\/ejhf.2947.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"5224_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ahj.2015.02.011","volume":"169","author":"C Russo","year":"2015","unstructured":"Russo C, Jin Z, Homma S, et al. Race-ethnic differences in subclinical left ventricular systolic dysfunction by global longitudinal strain: a community-based cohort study. Am Heart J. 2015;169(5):721\u20136. https:\/\/doi.org\/10.1016\/j.ahj.2015.02.011.","journal-title":"Am Heart J"},{"issue":"9","key":"5224_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1002\/ejhf.1220","volume":"20","author":"JF Nauta","year":"2018","unstructured":"Nauta JF, Hummel YM, van der Meer P, et al. Correlation with invasive left ventricular filling pressures and prognostic relevance of the echocardiographic diastolic parameters used in the 2016 ESC heart failure guidelines and in the 2016 ASE\/EACVI recommendations: a systematic review in patients with heart failure with preserved ejection fraction. Eur J Heart Fail. 2018;20(9):1303\u201311. https:\/\/doi.org\/10.1002\/ejhf.1220.","journal-title":"Eur J Heart Fail"},{"issue":"49","key":"5224_CR27","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1097\/MD.0000000000022683","volume":"99","author":"F Zhang","year":"2020","unstructured":"Zhang F, Liang Y, Chen X, et al. Echocardiographic evaluation of left ventricular end diastolic pressure in patients with diastolic heart failure: A comparative study with real-time catheterization. Med (Baltim). 2020;99(49):1536\u20135964. 10.1097\/ MD.0000000000022683.","journal-title":"Med (Baltim)"},{"issue":"11","key":"5224_CR28","doi-asserted-by":"publisher","first-page":"5384","DOI":"10.1097\/MS9.0000000000001287","volume":"85","author":"M Suleman","year":"2023","unstructured":"Suleman M, Saqib M, Mumtaz H, et al. Novel echocardiographic markers for left ventricular filling pressure prediction in heart failure with preserved ejection fraction (ECHO-PREDICT): a prospective cross-sectional study. Ann Med Surg. 2023;85(11):5384\u201395. https:\/\/doi.org\/10.1097\/MS9.0000000000001287.","journal-title":"Ann Med Surg"},{"issue":"2","key":"5224_CR29","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1211\/0022357001773715","volume":"52","author":"J Pataricza","year":"2000","unstructured":"Pataricza J, H\u2009~\u2009ohn J, Petri A, et al. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol. 2000;52(2):213\u20137. https:\/\/doi.org\/10.1211\/0022357001773715.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"5224_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10557-007-6070-y","volume":"21","author":"K Damman","year":"2007","unstructured":"Damman K, Voors AA. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz. Et al. J. 2007;21(6):403\u20134. https:\/\/doi.org\/10.1007\/s10557-007-6070-y.","journal-title":"J"},{"issue":"3","key":"5224_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2174\/1568016054368232","volume":"3","author":"IA Paraskevaidis","year":"2005","unstructured":"Paraskevaidis IA, Parissis JT, Th Kremastinos D. Anti-inflammatory and anti-apoptotic effects of Levosimendan in decompensated heart failure: a novel mechanism of drug-induced improvement in contractile performance of the failing heart. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(3):243\u20137. https:\/\/doi.org\/10.2174\/1568016054368232.","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"issue":"12","key":"5224_CR32","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1007\/s00210-023-02592-5","volume":"396","author":"LM Rayo-Abella","year":"2023","unstructured":"Rayo-Abella LM, Grundig P, Bernhardt MN, et al. OR-1896 increases force of contraction in the isolated human atrium. Naunyn Schmiedebergs Arch Pharmacol. 2023;396(12):3823\u201333. https:\/\/doi.org\/10.1007\/s00210-023-02592-5.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"23","key":"5224_CR33","doi-asserted-by":"publisher","first-page":"5169","DOI":"10.1111\/bph.12647","volume":"171","author":"O Orstavik","year":"2014","unstructured":"Orstavik O, Ata SH, Riise J, et al. Inhibition of phosphodiesterase-3 by Levosimendan is sufficient to account for its inotropic effect in failing human heart. Br J Pharmacol. 2014;171(23):5169\u201381. https:\/\/doi.org\/10.1111\/bph.12647.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"5224_CR34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ijcard.2011.07.022","volume":"159","author":"Z Papp","year":"2012","unstructured":"Papp Z, Edes I, Fruhwald S, et al. Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol. 2012;159(2):82\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2011.07.022.","journal-title":"Int J Cardiol"},{"issue":"5","key":"5224_CR35","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jchf.2021.01.015","volume":"9","author":"D Burkhoff","year":"2021","unstructured":"Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial[J]. JACC Heart Fail. 2021;9(5):360\u201370. https:\/\/doi.org\/10.1016\/j.jchf.2021.01.015.","journal-title":"JACC Heart Fail"},{"issue":"21","key":"5224_CR36","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1016\/j.jacc.2016.03.539","volume":"67","author":"DM Kaye","year":"2016","unstructured":"Kaye DM, Nanayakkara S, Vizi D, Byrne M, Mariani JA. Effects of milrinone on rest and exercise hemodynamics in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;67(21):2554\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.539.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5224_CR37","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1002\/ehf2.12908","volume":"7","author":"DM Kaye","year":"2020","unstructured":"Kaye DM, Byrne M, Mariani J, et al. Identification of physiologic treatment targets with favourable haemodynamic consequences in heart failure with preserved ejection fraction. ESC Heart Fail. 2020;7(6):3685\u201393. https:\/\/doi.org\/10.1002\/ehf2.12908.","journal-title":"ESC Heart Fail"},{"issue":"3","key":"5224_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0002-8703(03)00248-5","volume":"146","author":"JH McGowan","year":"2003","unstructured":"McGowan JH, Cleland JG. Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods. Am Heart J. 2003;146(3):388\u201397. https:\/\/doi.org\/10.1016\/S0002-8703(03)00248-5.","journal-title":"Am Heart J"},{"issue":"16","key":"5224_CR39","doi-asserted-by":"publisher","first-page":"e008455","DOI":"10.1161\/JAHA.117.008455","volume":"7","author":"L Lannemyr","year":"2018","unstructured":"Lannemyr L, Ricksten SE, Rundqvist B, et al. Differential effects of Levosimendan and Dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double-blind controlled trial. J Am Heart Assoc. 2018;7(16):e008455. https:\/\/doi.org\/10.1161\/JAHA.117.008455.","journal-title":"J Am Heart Assoc"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05224-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05224-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:05:08Z","timestamp":1767474308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05224-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5224"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05224-3","relation":{},"ISSN":["1471-2261"],"issn-type":[{"type":"electronic","value":"1471-2261"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"28 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was consented by the Committee of Clinical Investigation of Zhejiang Hospital (2024\u2013078\u00a0K) and conducted with the guidelines of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}